The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Subscribe To Our Newsletter & Stay Updated
